In the Purdue Pharma bankruptcy trial now underway, scrutiny has focused on the Sacklers' demand for immunity from opioid lawsuits that would extend to a vast network of individuals and businesses.

Companies that sold or distributed opioid medications face huge legal, financial and public relations peril. Critics say shareholders, not CEOs, will pay the price.